KALA BIO, Inc. entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell 2,928 Series F Convertible Non-Redeemable Preferred Stock at an issue price of $683 per preferred share for gross proceeds of $1,999,824 on December 21, 2023. The transaction is expected to close on December 22, 2023.